CliffBio
small molecule

FABIOR

TAZAROTENE

Loss of exclusivityFebruary 2030latest FDA-listed patent expiry
CompanyMayne Pharma →View the full company profile on CliffBio

Drug detail

Brand nameFABIOR
Active ingredientTAZAROTENE
Strength0.1%
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalMay 2012
Marketing statusRX

Listed patents

PatentExpiresType
10568859February 2030product
10688071February 2030product
8808716February 2030product

More from Mayne Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FABIOR patent cliff — loss of exclusivity February 2030 | CliffBio